Our Partners


In 2012, Inventiva signed a multi-year drug discovery collaboration with AbbVie, which was extended in 2017. Through this collaboration, Inventiva leverages upon its discovery expertise and technology platforms to develop drug candidates targeting the nuclear receptor ROR-y, a very promising approach for the treatment of several autoimmune diseases, specially psoriasis in its moderate to severe form.

This collaboration entitles Inventiva to receive research fees, milestone payments and sales royalties.